Core Viewpoint - Neumora Therapeutics, Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements and inadequate data regarding its clinical trials, leading to significant investor losses following the failure of its experimental depression treatment [4][5]. Group 1: Legal Actions and Investigations - Faruqi & Faruqi, LLP is investigating potential claims against Neumora and has set an April 7, 2025 deadline for investors to seek the role of lead plaintiff in the class action lawsuit [2]. - The lawsuit alleges that Neumora and its executives violated federal securities laws by making false statements and failing to disclose critical information about their clinical trials [4]. Group 2: Financial Impact - Following the announcement of the failure of its depression treatment in the Phase III Koastal-1 trial, Neumora's stock price dropped by 81%, closing at $1.97 per share on January 2, 2025 [5]. - Investors who suffered losses exceeding $50,000 due to the IPO and related documents are encouraged to contact the law firm for discussions on their legal rights [1]. Group 3: Clinical Trial Issues - The complaint highlights that Neumora had to amend the original Phase Two Trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder (MDD) to demonstrate the efficacy of navacaprant [4]. - It is claimed that the Phase Two Trials lacked adequate data, particularly regarding patient population size and gender ratio, which undermined the predictive accuracy for the subsequent KOASTAL-1 study [4].

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora’s September 2023 initial public offering (the “IPO”), of the important April 7, 2025 lead plaintiff deadline in the securities class action first filed by the firm. SO WHAT: If ...

NEW YORK, April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=140382&from=4 CLASS PERIOD: ...

Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. in the Southern District of New York, concerning alleged misleading statements in the company's Offering Documents related to its initial public offering [1] Group 1: Allegations Against Neumora - The lawsuit claims that Neumora made materially false and/or misleading statements in its Offering Documents [2] - It is alleged that Neumora amended the Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2] - The complaint also states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [2] Group 2: Lead Plaintiff Process - Investors in Neumora have until April 7, 2025, to seek appointment as a lead plaintiff representative of the class [3] - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3] - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3] Group 3: Contact Information - Kessler Topaz Meltzer & Check, LLP encourages affected Neumora investors to contact them for more information [4] - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4]

NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/ ...

Please visit our website to review more information and submit your transaction information. Investors can contact the law firm at no cost to learn more about recovering their losses The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. LOS ANGELES, March 31, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm adv ...

https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=139438&from=3 CLASS PERIOD: This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023. NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purch ...

NMRA DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") is ...

DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, in the Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend the original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder ("MDD") to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Neumora Therapeutics, Inc. about the April 7, 2025 deadline to join a securities class action lawsuit related to the company's September 2023 IPO [1][2]. Group 1: Class Action Details - Investors who purchased Neumora common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 7, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that the Offering Documents contained false or misleading statements, including the necessity for Neumora to amend trial criteria to justify its Phase Three Program [5]. - It is claimed that Neumora added a prespecified analysis to the Phase Two statistical analysis plan to focus on patients with moderate to severe major depressive disorder [5]. - The lawsuit also states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, impacting the predictability of the KOASTAL-1 study results [5].